{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-011454","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.422324+00:00","generated_at":"2026-05-27T00:27:51.829036+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Helix Acquisition Corp. II appoints Albert A. Holman, III to its Board of Directors","bullets":["Albert A. Holman, III appointed on Feb 8, 2025 as Class III independent director.","Holman brings life sciences investment banking experience; will serve on Audit Committee.","Sponsor transferred 30,000 Class B ordinary shares to Holman in connection with appointment.","Holman executed standard SPAC Letter Agreement and Joinder to Registration Rights Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-011454","json":"https://secwatch.observer/filing/0001213900-25-011454.json","markdown":"https://secwatch.observer/filing/0001213900-25-011454.md","text":"https://secwatch.observer/filing/0001213900-25-011454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025011454/0001213900-25-011454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025011454/ea0230467-8k_helixacq2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:27:51.829036+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}